BTC Capital Management Inc. Acquires Shares of 54,418 Boston Scientific Corporation $BSX

Key Points

• BTC Capital Management Inc. acquired a new stake in Boston Scientific Corporation worth approximately $5.83 million by purchasing 54,418 shares in the second quarter.
• Boston Scientific reported a quarterly earnings per share of $0.75, exceeding the analysts' consensus estimate of $0.72 and showing a year-over-year revenue growth of 22.8%.
• Analysts have recently upgraded their ratings for Boston Scientific, with target prices increased by multiple firms, some reaching as high as $133.00.

BTC Capital Management Inc. bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 54,418 shares of the medical equipment provider's stock, valued at approximately $5,834,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares during the last quarter. State of Wyoming increased its position in shares of Boston Scientific by 119.5% during the 4th quarter. State of Wyoming now owns 2,660 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 1,448 shares during the last quarter. Waverly Advisors LLC boosted its stake in Boston Scientific by 24.2% in the 4th quarter. Waverly Advisors LLC now owns 11,174 shares of the medical equipment provider's stock valued at $998,000 after purchasing an additional 2,179 shares during the period. Finally, Novem Group acquired a new position in shares of Boston Scientific during the 4th quarter worth $220,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last ninety days. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.39 during mid-day trading on Friday, reaching $97.84. 16,833,754 shares of the stock were exchanged, compared to its average volume of 8,405,870. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $144.97 billion, a P/E ratio of 58.24, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a 50 day simple moving average of $104.40 and a 200-day simple moving average of $102.10.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Truist Financial boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Wells Fargo & Company upped their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Finally, Leerink Partners began coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.